NNovo Nordisk Read More Amgen’s MariTide Aims to Cut Obesity Shots From 52 a Year to as Few as Four — BigGo Finance2026-11-08 Amgen is betting that convenience, not raw weight loss, can carve it a place in the crowded obesity…
NNovo Nordisk Read More Valeriia Simanovskaia: The GLP-1 Shake-Up Is Not Another Weight-Loss Drug — It’s What Happens After the Weight Is Lost — BigGo Finance2026-10-16 Eli Lilly sells the same molecule under two names — Mounjaro for diabetes, Zepbound for obesity — and…
NNovo Nordisk Read More AMGN’s MariTide: Can Convenience Drive its Obesity Market Share?2026-09-04 Amgen’s AMGN key pipeline candidate MariTide is a closely watched drug in the obesity market. The drug can…